Bleomycin for Injection — Class III drug recall D-0771-2021
Terminated recall by Hikma Pharmaceuticals USA Inc., reported 2021-09-01, distributed nationwide. Labeling: Not elsewhere classified: Mislabeling
| Recall number | D-0771-2021 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ, United States |
| Recall initiated | 2021-08-05 |
| Classified | 2021-08-26 |
| Reported by FDA | 2021-09-01 |
| Terminated | 2023-06-08 |
| Distributed | Nationwide (US) |
| Quantity | 1,152 vials |
| Reason classes | labeling |
| NDC | 00143-9240, 00143-9240-01, 00143-9241, 00143-9241-01 |
Product
Bleomycin for Injection, USP, packaged in 15 units per single dose vial, Rx only, Manufactured by Thymoorgan Pharmazie GmbH Schiffgraben 23, 38690 Gosfar, Germany Distributed by Hikma USA Inc. Berkeley Heights, NJ 07922, NDC 0143-9240-01
Reason for recall
Labeling: Not elsewhere classified: Mislabeling
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0771-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.